• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多囊卵巢综合征患者中口服避孕药加 GnRH 激动剂方案与口服避孕药加 GnRH 拮抗剂固定方案的 IVF/ICSI 结局:一项随机试验。

IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial.

机构信息

Division of Reproductive Endocrinology and IVF Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Baskent University, Sumer mah. 69168 sok. Grand Park Plaza C Blok kat:12 No:24 Seyhan, Adana, Turkey.

出版信息

Arch Gynecol Obstet. 2012 Sep;286(3):763-9. doi: 10.1007/s00404-012-2348-9. Epub 2012 May 9.

DOI:10.1007/s00404-012-2348-9
PMID:22569710
Abstract

OBJECTIVE

To compare the IVF/ICSI outcomes of the long GnRH agonist and the fixed GnRH antagonist protocol in women with PCOS.

DESIGN

Randomized controlled trial.

SETTING

Baskent University Department of Obstetrics and Gynecology.

PATIENTS

Three hundred women with PCOS.

INTERVENTIONS

IVF/ICSI following the long GnRH agonist down-regulation or the fixed GnRH antagonist protocols.

MAIN OUTCOME MEASURES

Ongoing pregnancy rates.

RESULTS

Ongoing pregnancy rates were 36.4 % in the OCP + GnRH agonist group and 35.9 % in the OCP + GnRH antagonist group (p > 0.05). Progesterone levels on the day of hCG (0.76 ± 0.71 vs. 0.58 ± 0.50), endometrial thickness on the day of hCG (11.57 ± 2.50 vs. 10.50 ± 2.01), total gonadotropin used (1388.71 ± 482.39 vs. 1253.25 ± 415.81), and duration of COH (9.07 ± 1.96 vs. 8.39 ± 1.75) were significantly lower in the OCP + GnRH antagonist group.

CONCLUSION

The OCP + long GnRH agonist and the OCP + fixed GnRH antagonist protocols yield similar ongoing pregnancy rates in women with PCOS. Although this study consisting three hundred patients, seems to be large enough in a single center, we were not able to reach to the actual size of power analysis which was approximately 3,000.

摘要

目的

比较长 GnRH 激动剂和固定 GnRH 拮抗剂方案在多囊卵巢综合征(PCOS)患者中的 IVF/ICSI 结局。

设计

随机对照试验。

地点

Baskent 大学妇产科。

患者

300 例 PCOS 患者。

干预措施

长 GnRH 激动剂下调或固定 GnRH 拮抗剂方案后的 IVF/ICSI。

主要观察指标

持续妊娠率。

结果

OCP+GnRH 激动剂组的持续妊娠率为 36.4%,OCP+GnRH 拮抗剂组为 35.9%(p>0.05)。HCG 日孕酮水平(0.76±0.71 比 0.58±0.50)、HCG 日子宫内膜厚度(11.57±2.50 比 10.50±2.01)、总促性腺激素用量(1388.71±482.39 比 1253.25±415.81)和 COH 持续时间(9.07±1.96 比 8.39±1.75)在 OCP+GnRH 拮抗剂组显著降低。

结论

OCP+长 GnRH 激动剂和 OCP+固定 GnRH 拮抗剂方案在 PCOS 患者中产生相似的持续妊娠率。尽管这项由 300 例患者组成的研究在单中心似乎足够大,但我们无法达到实际的功效分析规模,大约为 3000。

相似文献

1
IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial.多囊卵巢综合征患者中口服避孕药加 GnRH 激动剂方案与口服避孕药加 GnRH 拮抗剂固定方案的 IVF/ICSI 结局:一项随机试验。
Arch Gynecol Obstet. 2012 Sep;286(3):763-9. doi: 10.1007/s00404-012-2348-9. Epub 2012 May 9.
2
Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients.OCP 预处理后 GnRH 拮抗剂与长 GnRH 激动剂方案在 PCOS 患者中的比较。
Arch Gynecol Obstet. 2010 Sep;282(3):319-25. doi: 10.1007/s00404-010-1429-x. Epub 2010 Apr 9.
3
Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial.促性腺激素释放激素拮抗剂方案与长方案中口服避孕药的周期安排:一项随机对照试验。
Fertil Steril. 2011 Sep;96(3):590-3. doi: 10.1016/j.fertnstert.2011.06.022. Epub 2011 Jun 30.
4
Dual suppression with oral contraceptive pills in GnRH antagonist cycles for patients with polycystic ovary syndrome undergoing intracytoplasmic sperm injection.多囊卵巢综合征患者在接受卵胞浆内单精子注射的GnRH拮抗剂周期中使用口服避孕药进行双重抑制。
Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:137-40. doi: 10.1016/j.ejogrb.2014.10.033. Epub 2014 Oct 31.
5
GnRH agonist and antagonist protocols for stage I-II endometriosis and endometrioma in in vitro fertilization/intracytoplasmic sperm injection cycles.体外受精/卵胞浆内单精子注射周期中用于I-II期子宫内膜异位症和子宫内膜瘤的促性腺激素释放激素激动剂和拮抗剂方案。
Fertil Steril. 2007 Oct;88(4):832-9. doi: 10.1016/j.fertnstert.2006.12.046. Epub 2007 Apr 10.
6
Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.多囊卵巢综合征患者体外受精/卵胞浆内单精子注射周期中,常规 GnRH 拮抗剂方案与长 GnRH 激动剂方案的比较:系统评价和荟萃分析。
Sci Rep. 2022 Mar 15;12(1):4456. doi: 10.1038/s41598-022-08400-z.
7
[Effect of oral contraceptive pills upon IVF outcomes of patients under a short GnRH agonist protocol].[口服避孕药对短方案促性腺激素释放激素激动剂治疗患者体外受精结局的影响]
Zhonghua Yi Xue Za Zhi. 2010 Feb 23;90(7):454-7.
8
GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.促性腺激素释放激素激动剂(布舍瑞林)或人绒毛膜促性腺激素用于促性腺激素释放激素拮抗剂体外受精/卵胞浆内单精子注射周期的排卵诱导:一项前瞻性随机研究。
Hum Reprod. 2005 May;20(5):1213-20. doi: 10.1093/humrep/deh765. Epub 2005 Mar 10.
9
Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration.内源性黄体生成素血清水平对人绒毛膜促性腺激素注射日孕激素升高的影响。
Fertil Steril. 2011 Sep;96(3):600-4. doi: 10.1016/j.fertnstert.2011.06.061.
10
A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.一项关于在启动促性腺激素释放激素拮抗剂后增加重组促卵泡激素用于体外受精-胚胎移植的随机对照试验。
Fertil Steril. 2006 Jul;86(1):58-63. doi: 10.1016/j.fertnstert.2005.12.040. Epub 2006 Jun 6.

引用本文的文献

1
Optimizing Ovarian Stimulation for IVF in PCOS Patients: A Novel Day 1 GnRH Antagonist Protocol.优化多囊卵巢综合征患者体外受精的卵巢刺激:一种新型的第1天促性腺激素释放激素拮抗剂方案。
J Clin Med. 2025 Aug 21;14(16):5901. doi: 10.3390/jcm14165901.
2
Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis.辅助生殖的控制性卵巢刺激方案:一项网状荟萃分析。
Cochrane Database Syst Rev. 2025 Jul 1;7(7):CD012586. doi: 10.1002/14651858.CD012586.pub2.
3
Live birth rate of gonadotropin-releasing hormone antagonist versus luteal phase gonadotropin-releasing hormone agonist protocol in IVF/ICSI: a systematic review and meta-analysis.
促性腺激素释放激素拮抗剂与黄体期促性腺激素释放激素激动剂方案在体外受精/卵胞浆内单精子注射中的活产率:系统评价和荟萃分析。
Expert Rev Mol Med. 2023 Dec 14;26:e2. doi: 10.1017/erm.2023.25.
4
What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis.ART 治疗中卵巢刺激时最佳 GnRH 拮抗剂方案是什么?系统评价和网络荟萃分析。
Hum Reprod Update. 2023 May 2;29(3):307-326. doi: 10.1093/humupd/dmac040.
5
Ovarian stimulation with GnRH analogues.使用促性腺激素释放激素类似物进行卵巢刺激。
JBRA Assist Reprod. 2014 Jun 27;18(2):42-46. doi: 10.5935/1518-0557.20140003.
6
Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.多囊卵巢综合征患者体外受精/卵胞浆内单精子注射周期中,常规 GnRH 拮抗剂方案与长 GnRH 激动剂方案的比较:系统评价和荟萃分析。
Sci Rep. 2022 Mar 15;12(1):4456. doi: 10.1038/s41598-022-08400-z.
7
Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility.多囊卵巢综合征评估与管理国际循证指南:不孕症评估与治疗的证据总结及建议
Hum Reprod Open. 2019 Jan 4;2019(1):hoy021. doi: 10.1093/hropen/hoy021. eCollection 2019.
8
Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques.口服避孕药、孕激素或雌激素预处理用于接受辅助生殖技术的女性的卵巢刺激方案。
Cochrane Database Syst Rev. 2017 May 25;5(5):CD006109. doi: 10.1002/14651858.CD006109.pub3.
9
Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.用于辅助生殖技术的促性腺激素释放激素拮抗剂
Cochrane Database Syst Rev. 2016 Apr 29;4(4):CD001750. doi: 10.1002/14651858.CD001750.pub4.
10
Comparison of gonadotropin-releasing hormone agonist with GnRH antagonist in polycystic ovary syndrome patients undergoing in vitro fertilization cycle: Retrospective analysis from a tertiary center and review of literature.多囊卵巢综合征患者体外受精周期中促性腺激素释放激素激动剂与GnRH拮抗剂的比较:来自三级中心的回顾性分析及文献综述
J Hum Reprod Sci. 2014 Jan;7(1):52-7. doi: 10.4103/0974-1208.130852.